<DOC>
	<DOC>NCT01105598</DOC>
	<brief_summary>This Phase 1, double-blind (sponsor open) study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of ETC-1002 given to subjects with mild dyslipidemia.</brief_summary>
	<brief_title>A Multiple Ascending Dose Study of ETC-1002 in Subjects With Mild Dyslipidemia</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>Healthy male and female subjects of nonchild bearing potential as determined by medical history, physical examination, vital signs, ECG, and clinical laboratory measurements Fasting low density lipoproteincholesterol (LDLC) of 100160 mg/dL Fasting triglycerides (TG) of 100350 mg/dL (Cohort 5 only) Body Mass Index (BMI) of 1832 kg/m2 (Cohort 1 to 4 only) or 1836 (Cohort 5 only) and body weight &gt;50 kg Clinically significant disease that requires a physician's care and/or would interfere with study evaluations Alanine aminotransferase (ALT) or aspartate amino transferase (AST) &gt;1.2 x ULN; serum creatinine &gt;ULN; hemoglobin &lt;12.0 g/dL; other clinical lab tests (with the exception of ALT, AST, serum creatinine and hemoglobin) outside normal or protocol specified limits that are determined by the Investigator to be clinically significant Use of tobacco or tobacco products Use of any prescription or nonprescription drugs, vitamins, or dietary supplements within 14 days prior to randomization with the exception of lipid regulating drugs or supplements containing niacin &gt;500 mg/day or fish oil which will not have been used for 3 months prior to randomization Other exclusion criteria apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>